Targeted therapy in GIST: in silico modeling for prediction of resistance
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted therapy in GIST: in silico modeling for prediction of resistance
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 8, Issue 3, Pages 161-170
Publisher
Springer Nature
Online
2011-03-04
DOI
10.1038/nrclinonc.2011.3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors
- (2010) P. Schoffski et al. ANNALS OF ONCOLOGY
- Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region
- (2010) Yu Mi Ahn et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Biochemical and biophysical characterization of unique switch pocket inhibitors of p38α
- (2010) Steven L. Swann et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: An imaging, biochemical and molecular modeling study
- (2010) Palma Dileo et al. INTERNATIONAL JOURNAL OF CANCER
- A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number
- (2010) Annalisa Astolfi et al. LABORATORY INVESTIGATION
- Diverse somatic mutation patterns and pathway alterations in human cancers
- (2010) Zhengyan Kan et al. NATURE
- Even Better Kinase Inhibitors for Chronic Myeloid Leukemia
- (2010) Charles L. Sawyers NEW ENGLAND JOURNAL OF MEDICINE
- Rhabdomyosarcomatous Differentiation in Gastrointestinal Stromal Tumors After Tyrosine Kinase Inhibitor Therapy
- (2009) Bernadette Liegl et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Proapoptotic Activity of Bortezomib in Gastrointestinal Stromal Tumor Cells
- (2009) S. Bauer et al. CANCER RESEARCH
- Inhibitors of Deacetylases Suppress Oncogenic KIT Signaling, Acetylate HSP90, and Induce Apoptosis in Gastrointestinal Stromal Tumors
- (2009) T. Muhlenberg et al. CANCER RESEARCH
- Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib
- (2009) M. Montemurro et al. EUROPEAN JOURNAL OF CANCER
- Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl
- (2009) Eamonn F. Healy et al. FEBS LETTERS
- Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene
- (2009) Toshirou Nishida et al. International Journal of Clinical Oncology
- Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer
- (2009) Giuseppe Toffoli et al. JOURNAL OF CLINICAL ONCOLOGY
- Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies
- (2009) Jack A. Bikker et al. JOURNAL OF MEDICINAL CHEMISTRY
- T670X KIT Mutations in Gastrointestinal Stromal Tumors: Making Sense of Missense
- (2009) T. Negri et al. JNCI-Journal of the National Cancer Institute
- Activate and resist: L576P-KIT in GIST
- (2009) E. Conca et al. MOLECULAR CANCER THERAPEUTICS
- Targeted Therapies: The Rare Cancer Paradigm
- (2009) Marco A. Pierotti et al. Molecular Oncology
- Sequence and Structure Signatures of Cancer Mutation Hotspots in Protein Kinases
- (2009) Anshuman Dixit et al. PLoS One
- KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
- (2009) K. S. Gajiwala et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prognostic Stratification of High-risk Gastrointestinal Stromal Tumors in the Era of Targeted Therapy
- (2008) Cheol Keun Park et al. ANNALS OF SURGERY
- Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor
- (2008) Toshirou Nishida et al. CANCER SCIENCE
- Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor-Associated PDGFRAD842V Mutation
- (2008) B. Dewaele et al. CLINICAL CANCER RESEARCH
- Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors
- (2008) Narasimhan P. Agaram et al. GENES CHROMOSOMES & CANCER
- Clinical significance of oncogenicKITandPDGFRAmutations in gastrointestinal stromal tumours
- (2008) J Lasota et al. HISTOPATHOLOGY
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
- (2008) Michael C. Heinrich et al. JOURNAL OF CLINICAL ONCOLOGY
- Heterogeneity of kinase inhibitor resistance mechanisms in GIST
- (2008) B Liegl et al. JOURNAL OF PATHOLOGY
- Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases
- (2008) Jerzy Lasota et al. MODERN PATHOLOGY
- Protein kinase C-θ regulates KIT expression and proliferation in gastrointestinal stromal tumors
- (2008) W-b Ou et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now